RM-581, a small molecule in early developpement of a new class (the aminosteroids), demonstrated its ability to block the progression or even reduce the size of cancerous tumours that are difficult to treat with conventional chemothérapy. Le RM-581, une petite molécule en développement préclinique d'une nouvelle classe (les aminostéroïdes), a démontré une capacité à bloquer la progression ou même réduire réduire la taille des tumeurs cancéreuses difficiles à traiter avec la chimiothérapie classique.
| Website | http://www.neolyspharma.com |
| Employees | 9 (1 on RocketReach) |
| Founded | 2023 |
| Address | 2705 boul. Laurier, Québec, QC, Canada,, Quebec City, Quebec G1V 4G2, CA |
| Industry | Biotechnology Research |
| Keywords | Cancer Treatment, Oncology, Pharmaceutical Research, Drug Development, Clinical Trials, Small Molecule Drugs, Chemotherapy, Cancer Research, Biotechnology, Pharmaceutical, Innovative Therapies, Drug Discovery, Medical Research, Cancer Therapies, Pharmaceutical Development, Experimental Therapeutics |
| Competitors | Boehringer Ingelheim, Amgen, Roche, Genentech, Johnson & Johnson, Novartis, Sanofi, Merck & Co., Inc., GSK, Bristol Myers Squibb +48 more (view full list) |
Looking for a particular Neolys Pharma employee's phone or email?
Neolys Pharma Questions
Hugo Gagnon is the CEO of Neolys Pharma.
1 people are employed at Neolys Pharma.
Neolys Pharma is based in Quebec City, Quebec.
Top Neolys Pharma Employees
-
Hugo Gagnon
Chief Executive Officer at Neolys Pharma
Sherbrooke, QC, CA21
